Anti-NGF antibodies and methods using same
First Claim
Patent Images
1. An anti-nerve growth factor (NGF) antibody wherein said antibody:
- (a) binds NGF with a KD of less than about 2 nM;
(b) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 100 pM or less, wherein the IC50 is measured in the presence of about 15 pM human NGF; and
(c) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 10 pM or less, wherein the IC50 is measured in the presence of about 1.5 pM of NGF.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
-
Citations
33 Claims
-
1. An anti-nerve growth factor (NGF) antibody wherein said antibody:
-
(a) binds NGF with a KD of less than about 2 nM;
(b) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 100 pM or less, wherein the IC50 is measured in the presence of about 15 pM human NGF; and
(c) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 10 pM or less, wherein the IC50 is measured in the presence of about 1.5 pM of NGF. - View Dependent Claims (2, 3, 4, 5, 31, 32, 33)
-
-
6. An antibody comprising a heavy chain variable region comprising:
-
(a) a CDR1 region of SEQ ID NO;
9, wherein I34 is S, L, V A, or I; and
N35 is substituted with N, T or S;
(b) a CDR2 region of SEQ ID NO;
10, wherein M50 is I, G, Q, S, or L;
A62 is A, or S;
and L63 is L or V; and
(c) a CDR3 region of SEQ ID NO;
11, wherein Y100 is Y, L, or R;
wherein Y101 is Y or W;
wherein G103 is G, A, or S;
wherein T104 is T or S;
wherein S105 is S, A, or T;
wherein Y106 is Y, R, T, or M;
wherein Y107 is Y or F;
wherein F108 is F or W;
wherein D109 is D, N, or G; and
wherein Y110 is Y, K, S, R or T;
wherein the antibody binds NGF. - View Dependent Claims (7)
-
-
8. An antibody comprising a light chain variable region comprising:
-
(a) a CDR1 region of SEQ ID NO;
12, wherein S26 is S or F;
D28 is D, S, A, or Y; and
H32 is H, N, or Q;
(b) a CDR2 region of SEQ ID NO;
13, wherein I51 is I, T, V or A; and
S56 is S or T; and
(c) a CDR3 region of SEQ ID NO;
14, wherein K92 is K, H, R, or S; and
wherein Y96 is Y or R;
wherein the antibody binds NGF. - View Dependent Claims (9)
-
-
10. An antibody comprising (a) a heavy chain variable region comprising:
-
(i) a CDR1 region of SEQ ID NO;
9, wherein I34 is substituted with S, L, V A, or I; and
N35 is substituted with N, T or S;
(ii) a CDR2 region of SEQ ID NO;
10, wherein M50 is I, G, Q, S, or L;
A62 is A, or S; and
L63 is L or V; and
(iii) a CDR3 region of SEQ ID NO;
11, wherein Y100 is Y, L, or R;
wherein Y101 is Y or W;
wherein G103 is G, A, or S;
wherein T104 is T or S;
wherein S105 is S, A, or T;
wherein Y106 is Y, R, T, or M;
wherein Y107 is Y or F;
wherein F108 is F or W;
wherein D109 is D, N, or G;
wherein Y110 is Y, K, S, R or T; and
(b) a light chain variable region comprising;
(i) a CDR1 region of SEQ ID NO;
12, wherein S26 is S or F;
D28 is D, S, A, or Y; and
H32 is H, N, or Q;
(ii) a CDR2 region of SEQ ID NO;
13, wherein 151 is I, T, V or A; and
S56 is S or T; and
(iii) a CDR3 region of SEQ ID NO;
14, wherein S91 is S or E;
K92 is K, H, R, or S; and
wherein Y96 is Y or R;
wherein the antibody binds NGF. - View Dependent Claims (11, 12, 13, 14, 15, 16)
-
-
17. An antibody comprising a heavy chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
3;
(b) a CDR2 region shown in SEQ ID NO;
4; and
(c) a CDR3 region shown in SEQ ID NO;
5;
wherein the antibody binds NGF. - View Dependent Claims (18, 28, 29, 30)
-
-
19. An antibody comprising a light chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
6;
(b) a CDR2 region shown in SEQ ID NO;
7; and
(c) a CDR3 region shown in SEQ ID NO;
8;
wherein the antibody binds NGF. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27)
-
Specification